.png){kind=icon}
返回
Comprehensive genomic profiling: Does timing matter?
.png){kind=icon}
OA
AI
DOI：10.3389/fonc.2023.1025367.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
PurposeThere is variability in utilization of Comprehensive Genomic Profiling (CGP) in most of the metastatic solid tumors (MST). We evaluated the CGP utilization patterns and its impact on outcomes at an academic tertiary center. Patients and MethodsInstitutional database was reviewed for CGP data in adult patients with MST between 01/2012 - 04/2020. Patients were categorized based on interval between CGP and metastatic diagnosis; 3 tertiles of distribution (T1-earliest to the diagnosis, T3-furthest), and pre-mets (CGP performed prior to diagnosis of metastasis). Overall survival (OS) was estimated from the time of metastatic diagnosis with left truncation at the time of CGP. Cox regression model was used to estimate the impact of timing of CGP on survival. ResultsAmong 1,358 patients, 710 were female, 1,109 Caucasian, 186 Afro-Americans, and 36 Hispanic. The common histologies were lung cancer (254; 19%), colorectal cancer (203; 15%), gynecologic cancers (121; 8.9%), and pancreatic cancer (106; 7.8%). Time interval between diagnosis of metastatic disease and CGP was not statistically significantly different based on sex, race and ethnicity after adjusting for histologic diagnoses with 2 exceptions - Hispanics with lung cancer had delayed CGP compared to non-Hispanics (p =0.019) and females with pancreas cancer had delayed CGP compared to males (p =0.025). Lung cancer, gastro-esophageal cancer and gynecologic malignancies had better survival if they had CGP performed during the first tertile after metastatic diagnosis. ConclusionCGP utilization across cancer types was equitable irrespective of sex, race and ethnicity. Early CGP after metastatic diagnosis might have effect on treatment delivery and clinical outcomes in cancer type with more actionable targets.
Keyword:
comprehensive genomic profiling
metastatic solid tumors
disparities
best practice
precision oncology
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
3.3
论文数:
3.5W
被引数:
9.5W
机构
引用论文
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial基因型匹配临床试验对晚期实体瘤和患者预后的分子谱分析: Princess Margaret IMPACT/COMPACT试验.png)
GENOME MEDICINEOAAI
GENOME MEDICINEIF11.2
OAAI分享收藏The current state of molecular testing in the treatment of patients with solid tumors, 20192019实体瘤患者治疗中分子检测的现状OAAI
OAAI分享收藏f Institutional implementation of clinical tumor profiling on an unselected cancer populationf对未选择的癌症人群进行临床肿瘤分析的机构实施JCI INSIGHTOAAI
JCI INSIGHTIF6.1
OAAI分享收藏When should we order a next generation sequencing test in a patient with cancer?我们什么时候应该为癌症患者订购下一代测序测试？OAAI
OAAI分享收藏
没有更多内容
没有更多内容